Opus Genetics, Inc. Financial and Nonfinancial Liabilities, Fair Value Disclosure
Opus Genetics, Inc. (IRD) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $97.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $97.08M.
- 2026-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $77.35M.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $25.98M.
- 2020-09-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $110.78K.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $97.08M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $77.35M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $25.98M 10-Q · filed 2026-08-06 |
| 2020-09-30 | $110.78K 10-Q · filed 2020-10-29 |
| 2020-06-30 | $268.81K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $100.11K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $41.72K 10-Q · filed 2020-10-29 |
| 2019-09-30 | $123.87K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $366.73K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $794.22K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $2.31M 10-K · filed 2020-02-21 |
| 2018-09-30 | $4.10M 10-Q · filed 2018-11-02 |
| 2018-06-30 | $3.39M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $4.49M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $7.85M 10-K · filed 2019-03-07 |
| 2017-09-30 | $6.68M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $9.80M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $16.23M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $1.57M 10-K · filed 2018-03-09 |
| 2016-09-30 | $3.16M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $2.34M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $4.46M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $2.74M 10-K · filed 2017-02-24 |
| 2015-09-30 | $1.48M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $2.09M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $3.65M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $3.77M 10-K · filed 2016-03-14 |
| 2013-12-31 | $5.03M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |